Allo-SCT using BU, CY and melphalan for children with AML in second CR

作者：Beier R; Albert M H; Bader P; Borkhardt A; Creutzig U; Eyrich M; Ehlert K; Gruhn B; Greil J; Handgretinger R; Holter W; Klingebiel T; Kremens B; Lang P; Mauz Koerholz C; Meisel R; Mueller I; Peters C; Reinhardt D; Sedlacek P; Schulz A; Schuster F R; Schrauder A; Strahm B; Sykora K W; Woessmann W; Zimmermann M; Sauer M G^*

来源：Bone Marrow Transplantation, 2013, 48(5): 651-656.

DOI：10.1038/bmt.2012.204

• children
• AML
• BU
• CY
• melphalan
• CR2

Based on the results from the AML-BFM 98 trial, hematopoietic SCT (HSCT) is recommended for children with AML in second CR only. Here, we retrospectively analyze interphase data of children who underwent HSCT after myeloablative conditioning with BU, CY, and melphalan (BuCyMel) for AML in second remission (CR2) between 1998 and 2009. Out of 152 children, transplant data were available on 109 individuals. Sixty out of 109 children (55%) received BuCyMel. Median age at HSCT was 12.2 years (range 3.0; 18.3). GVHD prophylaxis mostly consisted of CsA and short term MTX with or without antithymocyte globulin. Matched-sibling donors were used for 6/60 analyzed recipients, the remainder either received grafts from matched unrelated (30/60) or mismatched donors. OS after 5 years was 62% (s.e. 6%), relapse incidence 35% (18/60 children) and treatment-related mortality accounted for 12% (7/60) of fatal events. In conclusion, even taking into account possible selection bias in this retrospective analysis, HSCT in CR2 using BuCyMel resulted in a respectable OS. Based on this data the prospective, controlled and centrally monitored AML SCT-BFM 2007 trial has started to recruit patients in January 2010 aiming to generate valid outcome data for further strategy decisions.

• 出版日期2013-5